All News

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

After Enhertu showed promising clinical trial results, the Food and Drug Administration agreed to speed up the development and review of the drug for certain patients with unresectable or metastatic breast cancer.

Chemotherapy-induced peripheral neuropathy is a common side effect of patients undergoing cancer treatment, though many patients are not fully informed about the condition before their therapy starts.

Well-meaning comments can come off as bothersome — or even hurtful — to me as I navigate cancer.

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

For the first time in three years, CURE® welcomed 500 attendees in person and hundreds more virtually to honor the 2022 Extraordinary Healer® award recipient.

The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.

From my “game-day uniform” to a playlist that made me feel ready to seize the day, here’s what helped me prepare for my days in cancer treatment.

Before being diagnosed with neuroendocrine cancer, I started to live a healthier life and took notice of some concerning symptoms.

Imfinzi alone is the standard of care in this patient population, however two combinations may have better outcomes.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

The majority of patients with relapsed/refractory large B-cell lymphoma were alive between four and five years after being treated with axi-cel.

The FDA granted a Fast Track designation to ofra-vec plus paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

If there was a certain diet that could prevent my daughter from going through the perils of chemotherapy, she’d do it in a heartbeat. But science doesn’t back the sugar-feeds-cancer myth.

Alex Mallonee has found it inspiring to depict his mother’s journey with breast cancer through art, and hopes others affected by cancer will feel the same.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

After my breast cancer metastasized to my lungs, I was put on a PARP inhibitor, which caused an unexpected side effect that, unfortunately, happens like clockwork.

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

An expert discusses the side effects patients with kidney cancer may experience from immunotherapy and tyrosine kinase inhibitor treatment, and how more research is needed in to ensure patients experience less side effects.

There are so many things I wish I’d known before being diagnosed with breast cancer, but if I’d known them all in advance, I wouldn’t have learned many valuable lessons.

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

I can’t plan anything without planning time to rest. I literally have to schedule my whole day around when I can lie down to nap.